Mineralys Therapeutics, Inc.
MLYS
$14.25
$0.755.56%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 23.82M | 20.65M | 18.30M | 16.26M | 14.30M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 192.40M | 168.35M | 134.51M | 105.08M | 84.66M |
Operating Income | -192.40M | -168.35M | -134.51M | -105.08M | -84.66M |
Income Before Tax | -177.81M | -153.25M | -119.67M | -90.80M | -71.90M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -177.81 | -153.25 | -119.67 | -90.80 | -71.90 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -177.81M | -153.25M | -119.67M | -90.80M | -71.90M |
EBIT | -192.40M | -168.35M | -134.51M | -105.08M | -84.66M |
EBITDA | -192.36M | -140.61M | -80.51M | -35.35M | -- |
EPS Basic | -3.64 | -3.27 | -2.71 | -2.19 | -1.99 |
Normalized Basic EPS | -2.28 | -2.05 | -1.69 | -1.37 | -1.25 |
EPS Diluted | -3.64 | -3.27 | -2.71 | -2.19 | -1.99 |
Normalized Diluted EPS | -2.28 | -2.05 | -1.69 | -1.37 | -1.25 |
Average Basic Shares Outstanding | 194.03M | 184.17M | 174.28M | 164.68M | 144.54M |
Average Diluted Shares Outstanding | 194.03M | 184.17M | 174.28M | 164.68M | 144.54M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |